Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Slides:



Advertisements
Similar presentations
Hematology The Study of Blood Blood contains cells, proteins, and sugars Red blood cells transport oxygen- erythrocytes White blood cells are part of the.
Advertisements

It’s All Good We All Have a Purpose Raise the Roof How Low Can You Go?
the Cox proportional hazards model (Cox Regression Model)
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.
Table 1. Serum Biomarkers
The heart and science of medicine.
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Patient A.
Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.
by Walter H. A. Kahr, and Yigal Dror
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Adjusted all-cause mortality risk by dialysate sodium (DNa) and predialysis serum sodium (SNa). Adjusted all-cause mortality risk by dialysate sodium (DNa)
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
One giant leap for pediatric AMKL
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
by Elham Kamangar, and Weiqiang Zhao
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Emerging roles for platelets as immune and inflammatory cells
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance by Elisabetta Antonioli, Paola Guglielmelli,
Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans by Tom van der Poll,
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Stage C or not stage C…? by Claire Dearden Blood
by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)‏ by Ahmed A. Daak, Carlton D. Dampier, Beng.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,
Overall survival by SCT versus observation in first complete remission
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms  Janine Prick, Gerald de Haan, Anthony R. Green,
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Immunoblots of PLCβ isoforms in wild-type and PLCβ2/β3-null platelets.
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
The estimated survival function using the Cox proportional hazards model and the mean value covariate pattern (days to recurrence, net tumor volume) for.
Importance of blood pressure control in hemodialysis patient survival
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Cumulative mortality risk in patients with 48-h blood urea nitrogen (BUN) levels of ≥8 mg/dl or
Rituximab immunotherapy: it’s getting personal
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.
Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.
Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.
Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study  Robert J. Cerfolio, MD, Ayesha.
Survival of children with sickle cell disease
by Jan J. Cornelissen, and Didier Blaise
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,
Stem cell transplant in MF: it’s time to personalize
Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.
Survival curves for patients prescribed no hypnotic are compared with survival curves for patients prescribed hypnotics, divided into four age groups (age.
Estimated survival probability curve in recipients of renal transplants in multivariable–adjusted Cox proportional hazard regression model 2. Estimated.
Cold agglutinin disease
Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.
Presentation transcript:

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Survival curves estimated from the Cox proportional hazard regression with time-dependent covariates. According to the model, each patient is initially assigned to a risk group and followed in that group as long as no changes in risk factors take place. The patient is reassigned to another risk group whenever further risk factors are acquired. So, each patient may contribute with some observation time to the estimate of survival in different risk groups. Therefore, the upper curve includes patients who did not acquire any risk factors during the whole follow-up (ie, hemoglobin level ≥ 100 g/L [10 g/dL], platelet count ≥ 100 × 109/L, or white blood cell count < 30 × 109/L). The other curves include patients who acquired 1, 2, or 3 factors during follow-up. Francesco Passamonti et al. Blood 2008;111:3383-3387 ©2008 by American Society of Hematology